Drug intelligence / Profile preview

docetaxel + vintafolide

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Intravenous

Overview

Docetaxel + vintafolide is a combination therapy consisting of docetaxel, a taxane chemotherapy agent, and vintafolide (EC145), a folate-targeted vinca alkaloid conjugate. Vintafolide is designed to deliver a cytotoxic agent (desacetylvinblastine hydrazide, DAVLBH) specifically to folate receptor (FR) positive cancer cells. The combination showed improved efficacy compared to either agent alone in FR-positive non-small cell lung cancer (NSCLC), particularly in patients with adenocarcinoma. The combination was evaluated in the Phase 2b TARGET trial.

Brand names: TaxotereDocefrezDocivyx
Other names: vintafolide/docetaxel

Targets

BCL-2 (BCL-2 family)FOLR1 (FRα)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on docetaxel + vintafolide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + vintafolide.

Explore the full profile